For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research and development | 1,204,090 | 1,283,956* | 1,143,178 | 1,839,176 |
| General and administrative | 1,677,697 | 1,186,379.5* | 1,846,495 | 1,849,130 |
| Change in fair value of related party note | 0 | -682,184.5* | 193,921 | 364,090 |
| Operating loss | -2,881,787 | -1,788,151* | -3,183,594 | -4,052,396 |
| Interest income, net | 80,834 | 96,997.5* | 55,151 | 348 |
| Other income (expense), net | 58,585 | -114,916.5* | 240,734 | -185,703 |
| Net loss | -2,742,368 | -1,806,070* | -2,887,709 | -4,237,751 |
| Foreign currency translation gain (loss) | 21,490 | -42,830.5* | 27,204 | -56,877 |
| Comprehensive loss | -2,720,878 | -1,848,900.5 | -2,860,505 | -4,294,628 |
| Basic EPS | -0.57 | -0.422 | -0.65 | -1.06 |
| Diluted EPS | -0.57 | -0.422 | -0.65 | -1.06 |
| Basic Average Shares | 4,797,833 | 4,386,156 | 4,443,262 | 3,981,992 |
| Diluted Average Shares | 4,797,833 | 4,386,156 | 4,443,262 | 3,981,992 |
MiNK Therapeutics, Inc. (INKT)
MiNK Therapeutics, Inc. (INKT)